MDMA (3,4-methylenedioxymethamphetamine) is an entactogen under investigation for PTSD treatment. Lykos Therapeutics' application for FDA approval was rejected in August 2024. Related compound methylone (via Transcend Therapeutics, acquired by Otsuka in March 2026) is in Phase 3.